AnaptysBio, Inc. Common Stock
ANABAnaptysBio, Inc. (ANAB) is a biotechnology company focused on developing therapeutic antibodies for immune-related conditions. Founded in 2005 and based in San Diego, California, the company utilizes innovative antibody discovery and engineering technologies to create novel biologics targeting inflammatory and immuno-oncology diseases. Its pioneering platform aims to address unmet medical needs through antibody therapeutics.
Company News
AnaptysBio filed a motion to dismiss Tesaro's anticipatory breach of contract claim in Delaware Chancery Court regarding their Collaboration Agreement over royalties from Jemperli (dostarlimab). Anaptys claims it sought good faith discussions to resolve alleged breaches by Tesaro and GSK, but Tesaro initiated a lawsuit without notice. The court i...
GSK's subsidiary Tesaro has filed a lawsuit against AnaptysBio in Delaware Chancery Court, alleging breach of a license agreement for the cancer drug Jemperli, and seeking to protect its royalty rights.
AnaptysBio filed a legal complaint in Delaware Chancery Court against Tesaro and GSK, alleging material breaches of their Collaboration Agreement, specifically related to PD-1 antagonist research and commercial efforts for the drug Jemperli.
Multiple health care stocks experienced significant price movements during Monday's after-market trading session, with some companies seeing notable gains while others experienced declines.
The psoriasis pipeline has several drugs in mid- and late-stage development, including Imsidolimab, TAK-279, and Sonelokimab, which are expected to positively impact the market. The treatment landscape is expanding with new therapies from various companies.
